Physician profile
Morgan Ebeling
NPI 1659864718
$8,039.34
in general payments reported to CMS, 2019-2025
34 companies · $2,245 in 2025
The $2,245 reported for 2025 was more than what 78% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $13.92 · 2021: $312 · 2022: $438 · 2023: $2,639 · 2024: $2,392 · 2025: $2,245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,885 · Education: $390.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,885.42 |
| Education | $390.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,220.99 | 2021-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $724.76 | 2023-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $631.67 | 2022-2025 | Ilumya, Odomzo, Blu-U |
| Novartis Pharmaceuticals Corporation | $588.07 | 2023-2025 | |
| Lilly USA, LLC | $569.59 | 2020-2025 | Taltz, Ebglyss, Olumiant |
| Genzyme Corporation | $526.76 | 2021-2025 | |
| Incyte Corporation | $523.54 | 2023-2025 | Opzelura |
| Ucb, INC. | $471.84 | 2023-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $431.64 | 2023-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $421.79 | 2022-2025 | Dupixent, Libtayo |
| Pfizer INC. | $383.05 | 2022-2025 | |
| Leo Pharma INC. | $277.18 | 2023-2025 | Adbry, Anzupgo |
| Amgen INC. | $156.12 | 2023-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $137.74 | 2021-2025 | Aklief, Nemluvio, Twyneo |
| Janssen Scientific Affairs, LLC | $130.39 | 2024 | Tremfya |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Strata Skin Sciences, INC. | $124.07 | 2024-2025 | Xtrac |
| Convatec INC. | $121.88 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $114.91 | 2021 | |
| Mayne Pharma Commercial LLC | $99.55 | 2025 | |
| Dermavant Sciences, INC. | $49.32 | 2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.74 | 2023 | Spevigo |
| Botanix Sb INC | $42.54 | 2025 | Sofdra |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $33.49 | 2023-2025 | Cabtreo, Jublia, Arazlo |
| Epi Health, LLC | $30.00 | 2022 | |
| Organon LLC | $23.56 | 2025 | Hadlima |
| Organogenesis INC. | $22.90 | 2024 | Affinity |
| Kerecis Limited | $20.93 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Biofrontera INC. | $19.91 | 2022 | |
| Almirall LLC | $19.51 | 2022 | |
| Verrica Pharmaceuticals INC. | $17.71 | 2024 | Ycanth |
| Fresenius Kabi USA, LLC | $17.06 | 2023 | |
| Journey Medical Corporation | $14.78 | 2022 | |
| Genentech USA, INC. | $13.18 | 2023 | Erivedge |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Ebeling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.